$59.77 -1.81 (%) AbbVie Inc - NYSE

Sep. 4, 2015 | 04:00 PM

Partner Headlines

  1. U.S. Food and Drug Administration Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies

    Benzinga | Sep. 1, 2015 | 07:30AM EST
  2. Baxalta Vs. AbbVie: Biopharma Spin-Off Battle

    GuruFocus | Aug. 20, 2015 | 12:01PM EST
  3. Dividend Investors Should Consider Johnson & Johnson

    GuruFocus | Aug. 19, 2015 | 18:36PM EST
  4. Benzinga's M&A Chatter for Wednesday August 19, 2015

    Benzinga | Aug. 19, 2015 | 18:27PM EST
  5. JNJ - Should It Be In Your Portfolio?

    GuruFocus | Aug. 19, 2015 | 12:13PM EST
  6. AbbVie: The Riskiest Dividend Aristocrat

    GuruFocus | Aug. 18, 2015 | 12:37PM EST
  7. First Eagle Investment Buys 19 Stakes in Second Quarter

    GuruFocus | Aug. 17, 2015 | 17:56PM EST
  8. Jim Cramer Advises His Viewers On Halozyme Therapeutics, CF Industries And Tower International

    Benzinga | Aug. 13, 2015 | 06:34AM EST
  9. First Eagle Fund Of America 2Q Commentary

    GuruFocus | Aug. 11, 2015 | 12:58PM EST
  10. What Company Will Be Fastest Growing Big-Cap Biotech?

    IBD | Aug. 5, 2015 | 14:58PM EST
  11. Google Regroups, Thunders Into Health Tech

    IBD | Jul. 31, 2015 | 08:02AM EST
  12. Gilead Gets Wall Street Love After Q2 Earnings Beat

    IBD | Jul. 29, 2015 | 12:29PM EST
  13. Gilead Q2 Earnings Soar As HCV Shines, HIV Rebounds

    IBD | Jul. 28, 2015 | 16:34PM EST
  14. Amgen Stock Clears Buy Point Ahead Of Earnings

    IBD | Jul. 28, 2015 | 14:33PM EST
  15. Benzinga's M&A Chatter for Monday July 27, 2015

    Benzinga | Jul. 27, 2015 | 18:39PM EST
  16. With The Teva Money, Allergan Could Engage In 'Large M&A' Next: Evercore ISI

    Benzinga | Jul. 27, 2015 | 16:25PM EST
  17. Biogen's Big-Volume Plunge Marks End Of 5-Year Run

    IBD | Jul. 24, 2015 | 13:26PM EST
  18. Biogen Plunges On Slashed Guidance; AbbVie Q2 Mixed

    IBD | Jul. 24, 2015 | 11:44AM EST
  19. Amazon Surges, Major Averages Set for Weekly Loss

    FoxBusiness | Jul. 24, 2015 | 09:30AM EST
  20. AbbVie Posts Upbeat Q2 Earnings, But Sales Miss Expectations

    Benzinga | Jul. 24, 2015 | 08:36AM EST
  21. Earnings Scheduled For July 24, 2015

    Benzinga | Jul. 24, 2015 | 04:51AM EST
  22. 10 Must Watch Stocks for Today

    Benzinga | Jul. 24, 2015 | 04:04AM EST
  23. Stocks Extend Losses; Amazon, Visa Headline After-Hours Action

    IBD | Jul. 23, 2015 | 17:06PM EST
  24. Illumina Breaches Key Level On Q2 Sales Miss

    IBD | Jul. 22, 2015 | 16:54PM EST
  25. What's Coming For Large-Cap Pharma Stocks This Earnings Season?

    Benzinga | Jul. 22, 2015 | 16:13PM EST
  26. Earnings Loom For Handful Of Top Big Cap 20 Stocks

    IBD | Jul. 20, 2015 | 18:50PM EST
  27. 6 Big-Cap Drugmakers Reporting Earnings Next Week

    IBD | Jul. 18, 2015 | 08:02AM EST
  28. Gilead's Fantastic Growth Expected To Slow

    IBD | Jul. 17, 2015 | 18:48PM EST
  29. It's Not Too Late To Buy Gilead Sciences

    GuruFocus | Jul. 17, 2015 | 12:01PM EST
  30. Fitbit Leads Trio Of Hot Health-Related IPO Stocks

    IBD | Jul. 15, 2015 | 17:50PM EST
  31. Top World Stocks In Bases Or Buy Range As Greece Votes

    IBD | Jul. 15, 2015 | 17:50PM EST
  32. Johnson & Johnson Profit Dips

    IBD | Jul. 14, 2015 | 18:54PM EST
  33. J&J Earnings Beat Views As Pharma Leads Way Again

    IBD | Jul. 14, 2015 | 11:18AM EST
  34. Big Cap 20: Biotech Red-Hot As Medicals Stay Dominant

    IBD | Jul. 13, 2015 | 18:43PM EST
  35. Allergan, Celgene Break Out As Other Medicals Base

    IBD | Jul. 13, 2015 | 18:43PM EST
  36. Don't Count Out Top Biotechs — They Still Got Game

    IBD | Jul. 10, 2015 | 18:05PM EST
  37. Juno, Celgene Lead 5 Top Biotechs Nearing Buy Point

    IBD | Jul. 1, 2015 | 17:43PM EST
  38. Can Hepatitis B Be A Blockbuster Bug?

    IBD | Jul. 1, 2015 | 08:02AM EST
  39. Enanta is growing thanks to collaborations.

    GuruFocus | Jun. 29, 2015 | 17:16PM EST
  40. Evercore ISI Analyst Breaks Down Amgen's IPR Against AbbVie's Humira Formulation Patent

    Benzinga | Jun. 29, 2015 | 14:44PM EST
  41. Acquisitions May Fuel Gilead Sciences' Winning Ways

    IBD | Jun. 26, 2015 | 17:28PM EST
  42. Intrexon, Enanta Among Top Biotech New Issues

    IBD | Jun. 24, 2015 | 17:19PM EST
  43. US Stock Futures Slide Ahead Of GDP Data

    Benzinga | Jun. 24, 2015 | 07:13AM EST
  44. AbbVie Reports Phase 3B Results in Genotype 1b Chronic Hep C Patients with Compensated Liver Cirrhosis

    Benzinga | Jun. 24, 2015 | 06:01AM EST
  45. Where Can Mega-Drug Stock Gilead Sciences Go Now?

    IBD | Jun. 22, 2015 | 13:56PM EST
  46. 5 NYSE Healthcare Stocks With The Highest ROE

    Benzinga | Jun. 22, 2015 | 09:29AM EST
  47. The Note Moving Pharma Giants Today

    Benzinga | Jun. 17, 2015 | 16:06PM EST
  48. New Report: Abbvie Is Jefferies' Top Global Pharma Stock

    Benzinga | Jun. 16, 2015 | 12:15PM EST
  49. AbbVie to Present Data from Studies of DUOPA Enteral Suspension in Advanced Parkinson's Disease During the International Congress of Parkinson's Disease and Movement Disorders

    Benzinga | Jun. 12, 2015 | 09:00AM EST
  50. Why Drugmaker AbbVie Can Power Past Patent Expiration

    IBD | Jun. 11, 2015 | 13:13PM EST
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!